Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| I think an off-the-shelf cell therapy program, even if at the same center as an autologous counterpart, certainly has some unique and distinct advantages |
| So we're excited about both product candidates |
| Fate Therapeutics is in a solid financial position to advance our pipeline |
| And we're very excited about that |
| And I think we are well positioned to treat the first patient in the coming weeks based on interactions that we've had with multiple sites |
| Clinical data previously presented by the company from the FT819 Phase 1 study in relapse refractory B-cell lymphoma showed a favorable safety profile and antitumor activity |
| I think that would be a significant breakthrough in the field, especially in thinking about treating patients with autoimmunity, essentially being able to decouple the requirement to administer intense chemotherapy conditioning to a patient and being able to deliver a cell therapy that could be delivered off-the-shelf and could achieve the same level or similar levels of B-cell reset without the conditioning |
| I'd also note that we've done a significant amount of work with CAR NK versus CAR T-cells pre-clinically, and we're very confident in essentially the homing and trafficking, and infiltration potential of our T-cell programs, iPS-derived CAR T-cell programs |
| We believe there is very strong value proposition for our iPSC product platform and off-the-shelf iPSC-derived cellular immunotherapies in autoimmunity, where a relatively short-lived cell can deeply eradicate an aberrant B-cell population and enable rapid reconstitution of a healthy immune system and where safety, patient convenience, and accessibility, cost and scale will be key differentiating factors |
| As we've sort of highlighted in the past with FT819, we've seen a really clean safety profile through multiple dose levels |
| And so I think that bodes very well for our potential to differentiate and reach patients with autoimmunity outside of the academic medical centers |
| So with respect to how FT819 is behaving in patients in vivo, we're really excited about that and think we have the potential to replicate what's been seen in a relatively small number of patients with autologous CAR T-cell therapy |
| We have product that's already been manufactured and can rapidly begin to intervene and treat patients, which we're super excited about |
| So we've been able to work successfully with several different oncology centers that are running FT819 and partner essentially the oncologist with the rheumatologists to gain momentum in starting the study |
| So we do think we are in a unique position given that we have a tremendous amount of oncology experience with FT819, we have relationships with key PIs on the oncology side, and that has enabled us to, I think, successfully partner with the rheumatologists |
| So super excited about that |
| Obviously, we think that is a significant milestone for the field of cell therapy, being able to deliver a cell therapy and allow it to thrive without conditioning chemotherapy |
| We believe FT825 represents an exciting new frontier in the field of cell-based cancer immunotherapy |
| I agree 522 is very exciting |
| Our cross-functional teams were able to respond to challenges, advance key clinical programs, and discover next-generation technologies and did so with efficiency |
| Additionally, we also plan to submit an investigational new drug application for FT522 in autoimmunity, where we think the potential to reduce chemotherapy conditioning and to target and deplete B cells, plasma cells, and autoreactive T-cells offers a highly differentiated therapeutic profile across a broad range of autoimmune diseases |
| So 522, we're super excited about that and the ADR technology |
| I think one of the advantages for us has been the fact that we are an oncology company, we do have good relationships with multiple centers NPIs that on the oncology side that have been conducting the 819 study, and they have been advocates and ambassadors for us in partnering with their rheumatologist cohorts |
| We believe our FT819 CAR T-cell program and our FT522 CAR NK cell program have the potential to durably deplete a patient's pathogenic immune cells, drive immune reset, and meaningfully improve quality of life across a wide spectrum of autoimmune diseases |
| So I think we're all excited about the potential in autoimmunity |
| I think we are encouraged based on what we've seen with respect to 819 and its resemblance to autologous CAR T-cell therapy, at least with respect to how the product performs in patients from a translational perspective |
| In its review of our application, CIRM scientific working group unanimously scored our application as having exceptional merit |
| Whether that be in hematologic malignancies or solid tumors, we've been able to deliver NK cells in the outpatient setting in the community |
| So given all of that, I think we're really comfortable with the profile that we've seen with FT819 on oncology, and I'm very excited about its potential in autoimmunity, where at least the data that exists in patients treated to date, primarily out of the group in Germany, has suggested that a short-lived cell, in their case an autologous program |
| Finally, we will review our financial position, where our operating discipline and strong cash balance have created the opportunity to continue our investment in developing a deep pipeline of highly differentiated preclinical and clinical product candidates, with the potential to bring significant therapeutic benefit to patients with cancer and autoimmune diseases |
| Statement |
|---|
| In the fourth quarter, our revenue declined to $1.7 million compared to $44.4 million for the same period last year |
| And yeah, there is going to be challenges in study start-up that we're all going to face and need to overcome |
| There are certainly, at least with respect to autologous CAR T-cell therapies, some safety concerns that have been raised generally in the field by the FDA |
| Our net loss for the fourth quarter was $44.1 million or $0.45 per share |
| Total operating expenses for the fourth quarter declined 54% from the same period last year to $49.8 million, which includes $9.5 million in non-cash share-based compensation expense |
| General and administrative expenses for the fourth quarter decreased by 17% from the same period last year to $17.9 million |
| The decline in our R&D expenses was attributable primarily to a decrease in salaries and benefits, including share-based compensation expense, following the company's restructuring in the first quarter of 2023 and from lower clinical trial costs and lower demand for R&D materials and equipment |
| I wonder if you can talk through the challenges you faced in these last six months, specifically getting these sites up and running |
| Do the enrollment criteria, do they set a new barrier for finding the right patient? Or how do you anticipate doing that? Scott Wolchko I think the enrollment, look, unfortunately, I mean, we're talking about in many instances where these autoimmune diseases are pretty severe and have had devastating consequences on patients' lives |
| Research and development expenses for the quarter decreased more than 60% from the same period last year to $31.8 million |
| And then maybe just secondly, assuming ADR technology is validated, is that something you could easily add to 819, or are there notable challenges there? Thank you |
| Just on kind of any guidance around SG&A and R&D, just considering it has declined significantly year-over-year |
| I think, you know, while it's always prudent to be cautious, we are dealing with CAR T-cell therapies |
| You're well aware of what's occurred recently with respect to the concern specifically around T-cell malignancies |
Please consider a small donation if you think this website provides you with relevant information